Background Regimen (BR)
Sponsors
Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.
Conditions
Tuberculosis, Multidrug-Resistant
Phase 2
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
SuspendedNCT02354014
Start: 2016-05-03End: 2028-11-02Target: 60Updated: 2026-09-17
An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
CompletedNCT02365623
Start: 2015-02-18End: 2018-11-08Updated: 2025-02-03